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The nearly ubiquitous exposure of the human
population to organophosphate pesticides has
raised increasing concern about their propen-
sity to elicit developmental neurotoxicity at
exposures that go undetected because of the
absence of systemic signs of intoxication
(Colborn 2006; Costa 2006; Landrigan 2001;
Mileson et al. 1998; Slotkin 2005; Weiss
et al. 2004). At high doses, inhibition of
cholinesterase leads to cholinergic hyperstimu-
lation and its associated symptoms (Mileson
et al. 1998), but the developing brain is tar-
geted by these agents at much lower expo-
sures. In large measure, the vulnerability of
the fetus and neonate reﬂects interference with
basic processes of neural cell replication and
differentiation, culminating in aberrant synap-
tic function and associated behavioral deﬁcits
(Barone et al. 2000; Pope 1999; Rice and
Barone 2000; Slotkin 2004). Importantly,
many of these effects involve mechanisms
unrelated to cholinesterase inhibition and are
elicited even at exposures below the threshold
for anticholinesterase actions (Pope 1999;
Slotkin 2004, 2005). In fact, rather than oper-
ating through a single defined mechanism,
organophosphates such as chlorpyrifos (CPF)
actually disrupt brain development through
several families of mechanisms, including
direct interactions with acetylcholine recep-
tors, interference with intracellular signaling
cascades that transduce receptor signals on the
cell surface into intracellular events, and
oxidative stress (Gupta 2004; Slotkin 1999,
2004, 2005; Yanai et al. 2002).
The diversity of mechanisms underlying
the developmental neurotoxicity of CPF and
the organophosphates is one of the main rea-
sons for the wide developmental window over
which the immature brain remains vulnerable
to these agents, ranging from the earliest stages
of brain formation through the postnatal con-
solidation of synaptic connections (Pope 1999;
Slotkin 2004, 2005). For the same reasons,
then, the standard countermeasures against
acute organophosphate poisoning, which are
aimed at the immediate reactivation of
cholinesterase and prevention of seizures (Shih
et al. 2003; Shih and McDonough 1999), are
unlikely to prove effective in preventing the
adverse effects on brain development associ-
ated with lower exposures of the population at
large. In the present study, we assessed the rela-
tive contributions of four distinct mechanisms
in the developmental neurotoxicity of organo-
phosphates by examining the ability of tar-
geted therapies to ameliorate the effects of
CPF: the combination of atropine plus
mecamylamine (antagonists toward muscarinic
and nicotinic acetylcholine receptors, respec-
tively); nicotine, which both stimulates and
desensitizes nicotinic receptors but also has
prooxidant and antioxidant characteristics
(Gitto et al. 2002; Guan et al. 2003; Qiao
et al. 2005; Xie et al. 2005) and promotes the
release of neurotrophic factors (Belluardo et al.
2000); the antioxidant vitamin E; and theo-
phylline, a phosphodiesterase inhibitor that
prevents the breakdown of cyclic AMP. Each
of these has a specific rationale for potential
use for amelioration of organophosphate-
induced developmental neurotoxicity.
Inhibition of cholinesterase produces choliner-
gic hyperstimulation because the excess acetyl-
choline interacts with muscarinic and nicotinic
receptors, and the organophosphates them-
selves interact directly with the receptors
(Gupta 2004). In addition to its direct actions
(stimulatory and inhibitory) on nicotinic
receptors, nicotine can protect neural cells by
blunting the antimitotic and prooxidant effects
of CPF (Qiao et al. 2003, 2005). Because CPF
produces part of its neurotoxicity through
oxidative mechanisms (Bagchi et al. 1995;
Crumpton et al. 2000b; Gupta 2004; Jett and
Navoa 2000; Qiao et al. 2005; Slotkin et al.
2005), classical antioxidants such as vitamin E
may also be protective, just as they are against
other oxidative stressors (Gultekin et al. 2001;
Qiao et al. 2005). Finally, interference with
the G-protein/adenylyl cyclase (AC) signaling
cascade, which is responsible for the synthesis
of cyclic AMP, is one of the main noncholiner-
gic pathways by which CPF evokes damage to
the developing brain (Slotkin 1999, 2004,
2005; Yanai et al. 2002). Accordingly, we
hypothesized that theophylline might have
ameliorating effects against the actions of CPF.
We conducted our evaluations in PC12
cells, a standard neurodevelopmental model
(Teng and Greene 1994) that reproduces
many of the key mechanisms and features of
the adverse effects of CPF on the developing
brain in vivo (Bagchi et al. 1995, 1996;
Crumpton et al. 2000a, 2000b; Das and
Barone 1999; Flaskos et al. 1994; Jameson
et al. 2006b; Li and Casida 1998; Nagata
et al. 1997; Qiao et al. 2001, 2005; Slotkin
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1999, 2004, 2005; Song et al. 1998; Tuler
et al. 1989; Yanai et al. 2002). Primary neu-
rons do not maintain their mitotic ability in
culture and differentiate in a heterogeneous
fashion; in contrast, PC12 cells enable detec-
tion of adverse effects on the cell cycle, an
important target for CPF and other organo-
phosphates (Slotkin 1999, 2004, 2005). With
the introduction of the neurotrophin nerve
growth factor (NGF), PC12 cells gradually
exit the mitotic cycle and differentiate into
cells with distinct neuronal phenotypes, pos-
sessing axonal projections, electrical excitabil-
ity, cholinesterase and cholinergic receptors
(Fujita et al. 1989; Song et al. 1998; Teng and
Greene 1994). Accordingly, the PC12 model
is suitable for examination of mechanisms
underlying adverse effects on multiple devel-
opmental stages ranging from cell replication
through end-stage neural differentiation. In
the present study, we examined the effects of
CPF with and without each of the ameliorat-
ing treatments on both undifferentiated and
differentiating PC12 cells with regard to DNA
synthesis, indices of cell number and size, and
AC signaling. Because each neural cell contains
a single nucleus, we measured DNA content to
evaluate the number of cells (Winick and
Noble 1965) and the protein/DNA ratio as an
index of cell size (Abreu-Villaça et al. 2005;
Jameson et al. 2006a; Slotkin et al. 2007; Song
et al. 1998). For AC measurements, we evalu-
ated basal enzymatic activity, the response to
global stimulation of G-proteins by ﬂuoride,
and maximal enzymatic activity elicited by
forskolin, which acts directly on AC, bypassing
the need for activation of neurotransmitter
receptors or G-proteins (Seamon and Daly
1986).
Material and Methods
Cell cultures. Because of the clonal instability of
the PC12 cell line (Fujita et al. 1989), we per-
formed the experiments using cells that had
undergone fewer than five passages, and all
studies were repeated several times with differ-
ent batches of cells. As described previously
(Crumpton et al. 2000a; Qiao et al. 2003; Song
et al. 1998), 3 × 106 PC12 cells (1721-CRL;
American Type Culture Collection; Manassas,
VA) were seeded onto 100-mm poly-D-lysine–
coated plates in RPMI-1640 medium
(Invitrogen, Carlsbad, CA) supplemented with
10% inactivated horse serum (Sigma Chemical
Co., St. Louis, MO), 5% fetal bovine serum
(Sigma Chemical Co.), and 50 µg/mL peni-
cillin/streptomycin (Invitrogen). Cells were
incubated with 7.5% CO2 at 37°C and the
medium was changed every 2 days. For studies
in the undifferentiated state, the medium was
changed 24 hr after seeding to include the vari-
ous test substances: CPF (Chem Service, West
Chester, PA), atropine plus mecamylamine,
nicotine, vitamin E, or theophylline (all from
Sigma Chemical Co.). Because of poor water
solubility, CPF was dissolved in dimethyl sul-
foxide (Sigma Chemical Co.) and vitamin E
was dissolved in 95% ethanol, achieving ﬁnal
respective concentrations of 0.1% and 0.05%,
respectively, in the culture medium; accord-
ingly, all control cultures also included the
appropriate vehicles, which had no effect on the
PC12 cells (Qiao et al. 2001, 2003; Song et al.
1998). For studies in differentiating cells,
3 × 106 cells were seeded, and 24 hr later, the
medium was changed to include 50 ng/mL
2.5 S murine NGF (Invitrogen); each culture
was examined under a microscope to verify the
subsequent outgrowth of neurites. The test
agents were added concurrently with the start
of NGF treatment, and cultures were main-
tained for 6 days, with the indicated agents
included with every medium change.
We chose the concentrations of test
agents on the basis of previous work. Given
our main objective of trying to prevent the
adverse effects of CPF, our strategy was to
elicit a robust response for each of the effects
to be evaluated. Accordingly, we used 30 or
50 µM CPF, concentrations high on the
dose–response curves for oxidative stress,
inhibition of DNA synthesis, and interference
with cell acquisition, but below the threshold
for outright cytotoxicity (Bagchi et al. 1995;
Crumpton et al. 2000b; Das and Barone
1999; Jameson et al. 2006b; Qiao et al. 2001,
2003, 2005; Slotkin et al. 2007; Song et al.
1998). Atropine and mecamylamine were
used at a concentration of 10 µM each, sub-
stantially higher than required for blockade of
muscarinic and nicotinic acetylcholine recep-
tors, respectively, but at levels devoid of
direct, adverse effects on PC12 cells (Song
et al. 1998). Nicotine was similarly tested at
10 µM, a concentration that provides partial
protection of PC12 cells against oxidative
stress and antimitotic effects of CPF (Qiao
et al. 2003, 2005). The antioxidant vitamin E
was evaluated at concentrations of 10 and
30 µM, as established for demonstrable pre-
vention of oxidative stress in earlier work
(Qiao et al. 2005). The phosphodiesterase
inhibitor theophylline was tested at both
1 and 10 mM, concentrations previously
found to affect the differentiation of MDA-
MB-231 cells, which, like PC12 cells, use
cyclic AMP as a differentiation signal (Slotkin
and Seidler 2000; Slotkin et al. 2000).
DNA synthesis. To initiate the measure-
ment of DNA synthesis, the medium was
changed to include 1 µCi/mL [3H]thymidine
(speciﬁc activity, 2 Ci/mmol; GE Healthcare,
Piscataway, NJ) along with the continued
inclusion of the test substances. After 1 hr, the
medium was aspirated and cells were harvested
in ice-cold water. Duplicate aliquots of each
sample were treated with 10% trichloroacetic
acid and sedimented at 1,000 × g for 15 min to
precipitate macromolecules. The resulting pel-
let was washed once with additional trichloro-
acetic acid and then with 75% ethanol. The
ﬁnal pellet was hydrolyzed with 1 M potassium
hydroxide overnight at 37°C and neutralized
with 6 M hydrochloric acid, and the DNA was
precipitated with ice-cold 5% trichloroacetic
acid and resedimented. The supernatant solu-
tion, comprising solubilized RNA and protein,
was discarded. The DNA-containing pellet was
hydrolyzed in 5% trichloroacetic acid for
15 min at 90°C and resedimented, and an
aliquot of the supernatant solution was
counted for radiolabel. Another aliquot was
assayed for DNA spectrophotometrically by
absorbance at 260 nm. Previous work has
demonstrated quantitative recovery of DNA by
these techniques (Bell et al. 1986; Slotkin et al.
1984). Incorporation values were corrected to
the amount of DNA present in each culture to
provide an index of DNA synthesis per cell
(Winick and Noble 1965).
DNA and protein content. For determina-
tions of DNA content and the protein/DNA
ratio, the medium was aspirated and the cul-
ture was rinsed with a buffer consisting of
154 mM sodium chloride and 10 mM sodium
phosphate (pH 7.4). Cells were harvested in
ice-cold buffer and homogenized (Polytron,
Brinkmann Instruments, Westbury, NY), and
aliquots were withdrawn for measurements of
DNA and protein using dye-binding methods
(Smith et al. 1985; Trauth et al. 2000).
Adenylyl cyclase activity. The AC assay
procedures and stimulant concentration pro-
ﬁles have been described in detail previously
(Auman et al. 2000; Meyer et al. 2005;
Zeiders et al. 1999). To prepare the cell
membrane fraction, the homogenates were
sedimented at 40,000 × g for 10 min and the
pellet was washed and resedimented. The
membrane pellets were resuspended using a
smooth glass homogenizer fitted with a
Teflon pestle, in a buffer consisting of
250 mM sucrose, 2 mM magnesium chloride,
and 50 mM Tris (pH 7.5). Incubations con-
tained 50 µg of membrane protein (Smith
et al. 1985) in a medium consisting of
40 mM Tris HCl (pH 7.4), 10 mM theo-
phylline, 1 mM adenosine 5´-triphosphate,
10 µM guanosine 5´-triphosphate, 2 mM
MgCl2, 1 mg/mL bovine serum albumin, and
a creatine phosphokinase-ATP-regenerating
system consisting of 10 mM sodium phos-
phocreatine and 8 IU/mL phosphocreatine
kinase (all from Sigma Chemical Co.), in a
total volume of 250 µL. The enzymatic reac-
tion was stopped by placing the samples in a
90–100°C water bath for 5 min, followed by
sedimentation at 3,000 × g for 15 min, and
the supernatant solution was assayed for cyclic
AMP by radioimmunoassay (GE Healthcare).
AC activity was evaluated under three differ-
ent conditions: basal activity, the response to10 mM NaF, and the response to 100 µM
forskolin (Sigma Chemical Co.).
Data analysis. Results are reported as
means and SEs. Because of the multiple treat-
ments in each experiment, significant differ-
ences were ﬁrst established by a global analysis
of variance (ANOVA) incorporating all treat-
ments, followed by Fisher’s protected least-
significant difference to evaluate differences
between speciﬁc treatment groups. Signiﬁcance
was assumed at the level of p < 0.05. To facili-
tate visual comparisons among the different
studies, all experiments were normalized so as
to share a standard set of control values, which
were calculated as the average across all the
experiments. The actual values varied by as
much as 50% among different platings of cells.
However, all statistical comparisons were con-
ducted on the original data.
Results
Atropine plus mecamylamine. In earlier work,
we showed that the combination of atropine
plus mecamylamine failed to prevent the
decline in DNA synthesis evoked by CPF
exposure in undifferentiated PC12 cells (Song
et al. 1998). In differentiating cells, exposure to
30 or 50 µM CPF for 6 days elicited a robust,
dose-dependent decrement in cell number as
assessed by DNA content (Figure 1A).
Although the combination of atropine plus
mecamylamine had no effect by itself, it pro-
vided significant but partial protection from
the adverse effects of CPF, reducing the impact
of the organophosphate by about 40%.
Accompanying the decrease in cell number,
CPF exposure caused a signiﬁcant increase in
the protein/DNA ratio (Figure 1B). For this
measure, the cholinergic antagonists by them-
selves also produced a partial effect, increasing
the ratio by about one-third of the effect seen
with CPF. Nevertheless, the atropine plus
mecamylamine combination still provided sig-
nificant protection against the CPF-induced
increase, reducing the value to that seen with
the antagonists alone.
CPF exposure also impaired AC signaling
in differentiating PC12 cells. For basal AC
activity, 30 µM CPF reduced activity by about
one-third (Figure 2A); the combination of
atropine plus mecamylamine had no effect by
itself, but in this case, failed to protect the cells
from the adverse actions of CPF. The effect of
CPF on fluoride-stimulated AC activity was
notably less than for basal activity (20%
decrease), but the same pattern was seen for
the cholinergic blocking agents: there was no
effect by themselves and no prevention of the
reduction caused by CPF (Figure 2B). For
forskolin-stimulated AC activity, CPF simi-
larly produced deﬁcits that were not blocked
by atropine plus mecamylamine (Figure 2C).
Nicotine. We previously showed partial
protection by nicotine against the antimitotic
effects of CPF in undifferentiated PC12 cells,
despite the fact that nicotine, by itself, had a
slight inhibitory effect (Qiao et al. 2003). In
differentiating PC12 cells, nicotine caused a
signiﬁcant deﬁcit in DNA content after 6 days
of exposure (Figure 3A). When nicotine was
coadministered with the lower concentration
of CPF (30 µM), the net outcome was similar
to the deficits seen with either treatment
alone, rather than showing the expected addi-
tive effect; this could imply some protection.
However, with the higher CPF exposure
(50 µM), there was a clear-cut worsening of
the outcome, with greater deﬁcits in cell num-
ber than were seen with either CPF or nico-
tine given separately. For the protein/DNA
ratio, nicotine by itself had no significant
effect, nor did it prevent the increase evoked
by CPF (Figure 3B). Nicotine also produced a
signiﬁcant decrement in basal AC activity, but
to a lesser extent than for CPF (Figure 4A).
Nicotine did not prevent the reduction caused
by CPF, but the combined effect was less than
would have been expected from additive
actions of the two individual agents. For ﬂuo-
ride-stimulated AC activity (Figure 4B) or
forskolin-stimulated activity (Figure 4C),
nicotine did not demonstrate any signiﬁcant
reversal of the effects of CPF.
Vitamin E. Because we had not previ-
ously evaluated the effects of vitamin E on
DNA synthesis in undifferentiated PC12
cells, we compared its effects alone or in com-
bination with CPF (Figure 5). At a concentra-
tion of 30 µM, CPF evoked significant
inhibition of DNA synthesis, in keeping with
Slotkin et al.
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Figure 2. Effects of 30 µM CPF with and without cotreatment with 30 µM atropine (ATR) plus 30 µM mecamylamine (MEC) on basal AC activity [A; ANOVA: treat-
ment, p < 0.0001 (n = 9–11)], ﬂuoride-stimulated AC activity [B; ANOVA: treatment, p < 0.0003 (n = 9–11)], and forskolin-stimulated AC activity [C; ANOVA: treatment,
p< 0.004 (n= 10–11)] in differentiating PC12 cells. Cells were treated with the indicated agents along with NGF for a total of 6 days. 
*Signiﬁcantly different from controls. #Cotreated values signiﬁcantly different from ATR plus MEC .
*
*#
14
12
10
8
6
B
a
s
a
l
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
Control
CPF 30 μM
ATR + MEC
CPF 30 μM
+ ATR + MEC
A
*
*#
160
140
120
100
80
60
F
l
u
o
r
i
d
e
-
s
t
i
m
u
l
a
t
e
d
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
Control
CPF 30 μM
ATR+MEC
CPF 30 μM
+ ATR + MEC
B
* *#
580
540
500
460
420
380
340
F
o
r
s
k
o
l
i
n
-
s
t
i
m
u
l
a
t
e
d
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
Control
CPF 30μM
ATR + MEC
CPF 30 μM
+ ATR + MEC
C
Figure 1. Effects of CPF (30 or 50 µM) with and without cotreatment with 30 µM atropine (ATR) plus 30 µM
mecamylamine (MEC) on DNA content [A; ANOVA: treatment, p < 0.0001 (n = 12–24)] and total protein/DNA
ratio [B; ANOVA: treatment, p < 0.0001 (n = 11–12)] in differentiating PC12 cells. Cells were treated with the
indicated agents along with NGF for a total of 6 days. 
*Signiﬁcantly different from controls. †Cotreated values signiﬁcantly different from CPF alone. #Cotreated values signiﬁcantly
different from ATR plus MEC. 
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*earlier findings (Qiao et al. 2001, 2003;
Slotkin et al. 2007; Song et al. 1998). By
itself, vitamin E also produced a dose-depen-
dent decrement, with an effect nearly equiva-
lent to that of CPF at the same concentration.
Nevertheless, vitamin E protected the cells
from the adverse effects of CPF. At either
10 or 30 µM vitamin E, the inhibition caused
by CPF was blunted, resulting in a net value
not distinguishable from the effect of
vitamin E alone but significantly different
from that of CPF alone. When vitamin E was
added during cell differentiation, we saw a
trend toward decreased DNA content, but
the effect was too small to achieve statistical
significance (Figure 6A). Again, this anti-
oxidant provided signiﬁcant protection from
the adverse effects of CPF. At the lower con-
centration (30 µM) of CPF, addition of either
10 or 30 µM vitamin E produced a net value
midway between that seen with either
vitamin E or CPF alone, so that the effects of
CPF were signiﬁcantly reduced. At the higher
CPF concentration (50 µM), 10 µM vitamin E
was ineffective but 30 µM vitamin E still pro-
duced signiﬁcant protection. We also evaluated
the protein/DNA ratio for the effects of 30 µM
CPF with and without vitamin E (Figure 6B);
for this parameter, vitamin E did not produce
any discernible protection from the increase
caused by CPF.
Surprisingly, vitamin E elicited deﬁcits in
basal AC activity quite similar to those seen
with CPF (Figure 7A). Here the combination
of CPF plus vitamin E resulted in even greater
loss of activity, so that rather than protecting
the cells from the adverse effects of CPF, the
actions were additive. A similar pattern was
seen for fluoride-stimulated AC activity
(Figure 7B) as well as the response to forskolin
(Figure 7C). In each case, vitamin E produced
inhibition similar to that seen with CPF and
either failed to prevent the effect of CPF (ﬂuo-
ride) or worsened the net effect (forskolin).
Theophylline. For theophylline, we also
evaluated the effects on DNA synthesis in
undifferentiated PC12 cells. By itself, this
agent caused massive reductions in the incor-
poration of [3H]thymidine into DNA: 8,863 ±
278 dpm/µg DNA for controls (n = 8), 3,638
± 133 for 1 mM theophylline (p < 0.0001,
n = 8), and 753 ± 43 for 10 mM theophylline
(p < 0.0001, n = 8). Accordingly, we were
unable to detect any potential ability of theo-
phylline to prevent the much smaller decre-
ment in DNA synthesis caused by CPF, but
this likely represents the technical limitation
imposed by the large effect of theophylline
by itself. In differentiating cells, theophylline
also had a significant adverse impact on cell
number as monitored by DNA content
(Figure 8A). The lower concentration (1 mM)
produced a deficit similar to that caused by
30 µM CPF alone and raising the theo-
phylline concentration to 10 mM resulted in a
decline of almost 90%. The combination of
30 µM CPF with 1 mM theophylline pro-
duced an additive deficit in cell number, so
that the DNA content was signiﬁcantly lower
than with either agent by itself. However,
when the CPF concentration was raised to
50 µM, theophylline provided signiﬁcant pro-
tection, so that the net value was midway
between that seen with theophylline alone or
CPF alone.
Equally dramatic effects of theophylline
were seen for measures of AC activity. By
itself, 1 mM theophylline evoked significant
up-regulation of basal AC activity, so that the
addition of this agent reversed the inhibitory
effects of CPF completely (Figure 9A).
Essentially the same reversal was obtained for
fluoride-stimulated AC activity (Figure 9B)
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Figure 4. Effects of 30 µM CPF with and without cotreatment with 10 µM nicotine (NIC) on basal AC activity [A; ANOVA: treatment, p < 0.0001 (n = 10–12)] , ﬂuoride-
stimulated AC activity [B; ANOVA: treatment, not signiﬁcant (n = 11–12)], and forskolin-stimulated AC activity [C; ANOVA: treatment, p < 0.004 (n = 10–12)] in differen-
tiating PC12 cells. Cells were treated with the indicated agents along with NGF for a total of 6 days. 
*Signiﬁcantly different from controls. #Cotreated values signiﬁcantly different from NIC alone.
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Figure 3. Effects of 30 µM or 50 µM CPF with and without cotreatment with 10 µM nicotine (NIC) on DNA
content [A; ANOVA: treatment, p < 0.0001 (n = 12–30)] and total protein/DNA ratio [B; ANOVA: treatment,
p < 0.0002 (n = 16–18)] in differentiating PC12 cells. Cells were treated with the indicated agents along with
NGF for a total of 6 days.
*Signiﬁcantly different from controls. #Cotreated values signiﬁcantly different from NIC alone.
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Figure 5. Effects of 30 µM CPF with and without
cotreatment with 10 or 30 µM vitamin E (VitE) on
DNA synthesis in undifferentiated PC12 cells.
ANOVA: treatment, p < 0.0001 (n = 5–16). Cells were
treated with the indicated agents for 24 hr, and
then [3H]thymidine incorporation into DNA was
measured for 1 hr.
*Significantly different from controls. †Cotreated values
signiﬁcantly different from CPF alone.
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*and for the forskolin response (Figure 9C). In
each case, theophylline produced a signiﬁcant
elevation that completely offset the effect of
CPF, even to the extent of producing a net
increase in activity from the combined expo-
sure for the basal and ﬂuoride measurements.
Discussion
Our ﬁndings support the concept that multi-
ple mechanisms contribute to the net adverse
effects of CPF on neural cell development
both in the undifferentiated state and during
differentiation into neuronal phenotypes. In
earlier studies with undifferentiated PC12 cells
(Song et al. 1998), we found that blockade of
acetylcholine receptors with atropine plus
mecamylamine failed to prevent the decline in
mitotic index elicited by CPF exposure, indi-
cating essentially no contribution of
cholinesterase inhibition and cholinergic
hyperstimulation to this end point. In con-
trast, in the present study, when we intro-
duced NGF to initiate differentiation, the
cholinergic antagonists provided partial pro-
tection against the deﬁcits in cell numbers, as
evidenced by a reduced effect of CPF on
DNA content. Thus, there is a transition in
contributory mechanisms to the adverse effects
of CPF, with relatively little reliance on
cholinergic hyperstimulation in the undiffer-
entiated state, but there is a signiﬁcant role for
this component once neural cell differentia-
tion gets under way. Our ﬁndings are conso-
nant with the increased role of cholinergic
factors in the effects of CPF on later versus
earlier stages of brain development in vivo
(Whitney et al. 1995) and are further rein-
forced by the results for nicotine, which
stimulates nicotinic acetylcholine receptors
directly. In undifferentiated PC12 cells, nico-
tine has only a small effect on DNA synthesis,
but with the initiation of differentiation this
effect becomes much larger (Qiao et al. 2003).
Furthermore, rather than producing additive
effects on DNA synthesis, nicotine actually
protects undifferentiated cells from the adverse
effects of CPF (Qiao et al. 2003), indicating
that the antimitotic actions depend on other
mechanisms. In the present study, we tried the
same strategy in differentiating PC12 cells and
instead found a mixed effect, just as would be
expected from additive cholinergic hyper-
stimulation from the two agents, superimposed
on noncholinergic, protective actions of nico-
tine (e.g., antioxidant properties). The combi-
nation of 30 µM CPF plus 10 µM nicotine
produced a decrement in DNA content indis-
tinguishable from that achieved by either agent
alone, but clearly less than would be antici-
pated from additive deﬁcits. However, raising
the CPF concentration to 50 µM resulted in
the expected cumulative effects.
The obvious issue, then, is to identify the
noncholinergic mechanism or mechanisms
that are superimposed on the cholinergic com-
ponents. Nicotine possesses both prooxidant
and antioxidant properties that depend both
on its concentration and on the underlying
cellular oxidative status (Gitto et al. 2002;
Guan et al. 2003; Qiao et al. 2005; Xie et al.
2005). Thus, although nicotine itself can pro-
duce oxidative stress in otherwise untreated
PC12 cells (Abreu-Villaça et al. 2005), it limits
the ability of CPF to produce even greater
stress (Qiao et al. 2005). We therefore rea-
soned that, if the mixed effect of nicotine
reflected the combination of antioxidant
actions superimposed on cholinergic hyper-
stimulation, then a pure antioxidant such as
vitamin E might demonstrate clear protection.
Indeed, in undifferentiated cells, where the
cholinergic contribution is low, vitamin E pro-
duced substantial protection against the anti-
mitotic effects of CPF. In differentiating cells,
Slotkin et al.
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Figure 7. Effects of 30 µM CPF with and without cotreatment with 10 or 30 µM vitamin E (VitE) on basal AC activity [A; ANOVA: treatment, p < 0.0001 (n = 7–8)], ﬂuoride-
stimulated AC activity [B; ANOVA: treatment, p < 0.01 (n = 6–8)], and forskolin-stimulated AC activity [C; ANOVA: treatment, p < 0.0001 (n = 7–9)] in differentiating PC12
cells. Cells were treated with the indicated agents along with NGF for a total of 6 days.
*Signiﬁcantly different from controls. †Cotreated values signiﬁcantly different from CPF alone. #Cotreated values signiﬁcantly different from VitE alone.
*
*#
14
12
10
8
6
B
a
s
a
l
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
Control
CPF 30 μM
A 160
140
120
100
80
60
F
l
u
o
r
i
d
e
-
s
t
i
m
u
l
a
t
e
d
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
) B
*
580
540
500
460
420
380
340
F
o
r
s
k
o
l
i
n
-
s
t
i
m
u
l
a
t
e
d
 
A
C
 
a
c
t
i
v
i
t
y
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
) C
* *
*†#
VitE 10 μM
VitE 30 μM
CPF 30 μM
+ VitE 10 μM
CPF 30 μM
+ VitE 30 μM
Control
CPF 30 μM
VitE 10 μM
VitE 30 μM
CPF 30 μM
+ VitE 10 μM
CPF 30 μM
+ VitE 30 μM
* * *
*†#
*
*
*
*†#
Control
CPF 30 μM
VitE 10 μM
VitE 30 μM
CPF 30 μM
+ VitE 10 μM
CPF 30 μM
+ VitE 30 μM
Figure 6. Effects of 30 or 50 µM CPF with and without cotreatment with 10 or 30 µM vitamin E (VitE) on DNA content [A; ANOVA: treatment, p < 0.0001 (n = 8–16)]
and total protein/DNA ratio [B; ANOVA: treatment, p < 0.0004 (n = 8)] in differentiating PC12 cells. Cells were treated with the indicated agents along with NGF for
a total of 6 days.
*Signiﬁcantly different from controls. †Cotreated values signiﬁcantly different from CPF alone. #Cotreated values signiﬁcantly different from VitE alone.
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VitE 10 μMthere was similarly a clear-cut beneﬁcial effect
in preventing the decline in DNA content,
with progressively more vitamin E required as
the CPF concentration was raised. These
results demonstrate conclusively that oxidative
stress plays a pivotal role in the noncholinergic
component of CPF’s interference with cell
cycle and maintenance of appropriate numbers
of neural cells. Nevertheless, there were poten-
tial problems in pursuing a strategy relying
solely on preventive effects of vitamin E. At the
higher concentration of 30 µM, vitamin E by
itself caused signiﬁcant reductions in mitotic
index in undifferentiated cells and a tendency
toward reduced DNA content in differentiat-
ing cells. Intracellular oxidative status increases
substantially during the transition from cell
replication to differentiation (Abreu-Villaça
et al. 2005; Qiao et al. 2005) and naturally
occurring oxidative stress may actually be
involved in many of the cellular events associ-
ated with these events (Katoh et al. 1997).
Thus, as with nicotine, the actions of anti-
oxidants such as vitamin E may be dual in
nature, with protective actions against CPF but
some adverse effects by themselves.
Cyclic AMP provides one of the major
endogenous signals for the switch from 
neural cell replication to differentiation (Mark
and Storm 1997; McManus et al. 1999;
Stachowiak et al. 2003), and CPF targets
G-protein coupled receptors, G-proteins, and
adenylyl cyclase as major noncholinergic
components of its effects on brain develop-
ment (Gupta 2004; Slotkin 1999, 2004,
2005; Yanai et al. 2002). Accordingly, it is
not surprising that we found gross inhibition
of DNA synthesis in undifferentiated PC12
cells upon addition of theophylline, a
phosphodiesterase inhibitor that enhances the
intracellular cyclic AMP concentration. In
differentiating cells, however, we found a
mixed effect as would be anticipated from a
combination of the direct actions of theo-
phylline but protection against the adverse
effects of CPF. With 30 µM CPF plus 1 mM
theophylline, the net reduction in DNA con-
tent was roughly equivalent to the additive
effects of the two agents. However, at the
higher CPF concentration (50 µM), theo-
phylline provided clear but partial protection,
reducing the deﬁcits to midway between the
two separate treatments, demonstrably less
than would have been anticipated from addi-
tive effects. The net result thus resembles that
seen with nicotine, where the direct effect of
the therapeutic intervention has some adverse
actions but nevertheless protects from further
injury by CPF. In contrast, though, at the
higher theophylline concentration (10 mM),
the adverse effects of theophylline itself were
so large as to obscure any potential benefit
when combined with CPF.
Although CPF has robust effects on cell
replication and cell number, it does not reduce
cell growth until much higher concentrations
than those in the current study are used (Song
et al. 1998). In differentiating PC12 cells, cell
enlargement occurs in part because of the gen-
eration of neuritic projections, an essential part
of the transition to the neuronal phenotype
(Teng and Greene 1994). Although CPF inter-
feres with axonogenesis, it can promote forma-
tion of shorter neuritic projections so that the
effects on neurite formation are mixed at con-
centrations such as those used here (Das and
Barone 1999; Howard et al. 2005; Song et al.
1998). Accordingly, although CPF caused a
substantial reduction in DNA content, the
protein/DNA ratio was increased by CPF
exposure; this increase was to a lesser extent
than the reduction in DNA content, implying
that there are indeed direct effects of CPF on
the protein components over and above the
Ameliorating chlorpyrifos neurotoxicity
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Figure 9. Effects of 30 µM CPF with and without cotreatment with 1 mM theophylline (Theo) on basal AC activity [A; ANOVA: treatment, p < 0.0001 (n = 8–10)], ﬂuoride-
stimulated AC activity [B; ANOVA: treatment, p < 0.0001 (n = 8–10)], and forskolin-stimulated AC activity [C; ANOVA: treatment, p < 0.0001 (n = 9–10)] in differentiating
PC12 cells. Cells were treated with the indicated agents along with NGF for a total of 6 days.
*Signiﬁcantly different from controls. †Cotreated values signiﬁcantly different from CPF alone. #Cotreated values signiﬁcantly different from Theo alone.
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Figure 8. Effects of 30 or 50 µM CPF with and without cotreatment with 1 or 10 mM theophylline (Theo) on DNA content [A; ANOVA: treatment, p < 0.0001
(n = 11–22)] and total protein/DNA ratio [B; ANOVA: treatment, p < 0.0001 (n = 11–12)] in differentiating PC12 cells. Cells were treated with the indicated agents
along with NGF for a total of 6 days. Note the difference in scale from the other ﬁgures.
*Signiﬁcantly different from controls. †Cotreated values signiﬁcantly different from CPF alone. #Cotreated values signiﬁcantly different from Theo alone.
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*†#impairment of cell acquisition. The combina-
tion of atropine plus mecamylamine also pro-
duced an increase in the ratio, albeit smaller
than that caused by CPF. Importantly, though,
the blocking agents produced a partial reversal
of the increase in protein/DNA ratio elicited by
CPF, bringing the value down to that seen with
just atropine plus mecamylamine. However,
for the other agents, there was a different out-
come. Neither nicotine nor vitamin E by them-
selves had any effect (unlike their actions on
DNA synthesis and content) and they also
failed to provide any protection against CPF.
Theophylline evoked an increase in the ratio,
but when combined with CPF the effects were
additive. Thus, only one of the strategies that
were successful in providing partial protection
against CPF for DNA synthesis and content
worked for the effects on this index of cell
growth and neurite formation.
The third target we examined was AC
activity. Consistent with its effects in the
developing brain (Slotkin 1999, 2004, 2005;
Song et al. 1997; Yanai et al. 2002), CPF
elicited deﬁcits in AC signaling in differenti-
ating PC12 cells. Here, though, neither the
cholinergic antagonists nor nicotine proved
beneficial in protecting the cells from CPF.
Vitamin E had deleterious actions, and when
used in combination with CPF, the deficits
were additive. The only promising result was
obtained with theophylline, and that was
because it evoked a substantial increase in AC
by itself. When superimposed on the adverse
effects of CPF, the stimulation evoked by
theophylline thus restored AC activity to nor-
mal or supranormal values. This is likely to
play an important role in neuroprotection
against organophosphates: forskolin, which
stimulates adenylyl cyclase directly, preserves
neural cells from the adverse effects of diiso-
propylﬂuorophosphate, potentially by promo-
tion of differentiation, which up-regulates
acetylcholinesterase itself (Curtin et al. 2006).
In addition, we found that CPF affected the
response to fluoride significantly less than it
did basal AC activity. Fluoride maximally
activates both stimulatory (Gs) and inhibitory
(Gi) G-proteins; this result implies that the
organophosphate treatment produces a shift
in the relative expression and/or function of
Gs and Gi, which would likely influence the
activities of receptors that stimulate or inhibit
AC. Although we did not pursue this issue in
the present study, it is clearly an important
consideration for future work, both in terms
of additional mechanisms for CPF-induced
developmental neurotoxicity and for contri-
butions to subsequent neurotransmitter
mechanisms underlying behavioral anomalies.
In the developing brain, the neurotoxicity
of CPF undergoes distinct transitions in
mechanisms and cellular targets, so that
although adverse effects are elicited at virtually
any maturational stage, the regions, neuro-
transmitters, and behaviors that are affected
shift according to the period in which expo-
sure occurs (Slotkin 1999, 2004, 2005). Here,
with the PC12 model, we were able to identify
the critical stages in which some of these
diverse mechanisms operate and consequently
to evaluate speciﬁc amelioration strategies that
might provide protection against the adverse
effects of CPF. Importantly, each of the mech-
anisms made a partial contribution to the net
outcome for either neural cell replication or
differentiation. Cholinergic antagonists,
although totally ineffective in preventing the
antimitotic effects of CPF in undifferentiated
cells (Song et al. 1998), were successful once
differentiation was under way, in partially
reversing the deficits in cell number and the
rise in protein/DNA ratio; this is entirely con-
sistent with the transition to a cholinergic
phenotype in PC12 cells (Jameson et al.
2006a, 2006b; Teng and Greene 1994) and
with the increasing role of cholinergic mecha-
nisms in the adverse effects of CPF in vivo as
brain development progresses (Slotkin 1999,
2004, 2005; Whitney et al. 1995). Nicotine
was partially effective in protecting cell repli-
cation in undifferentiated cells but likely
through antioxidant actions (Qiao et al.
2005), so that a similar effect was found with
vitamin E. With increasing differentiation,
the effects of nicotine acting as a cholinergic
agonist offset some of the positive conse-
quences of its antioxidant actions, so that the
remaining beneficial effect depended on
whether the CPF concentration was low or
high. For nicotine, too, any potential value
for amelioration of organophosphate-induced
neurodevelopmental injury must be tempered
by the fact that nicotine itself is a neuro-
teratogen (Slotkin 1999, 2004); this will limit
its utility to short-term use. Alternatively, fur-
ther mechanistic investigations may enable
substitution of analogs that preserve the pro-
tectant effects while reducing the direct,
adverse impact on neurodevelopment.
Nicotine is also generally neuroprotectant in
the intact brain by causing the release of
neurotrophic factors (Belluardo et al. 2000),
an effect that we would not likely detect in a
monoculture of PC12 cells; this implies that,
used properly, nicotine or nicotine analogs
may be even more effective in vivo than seen
here. Similar to nicotine, vitamin E had com-
plex effects after addition of NGF because,
although it protected the cells from oxidative
stress caused by CPF, it also interferes with
the role of endogenous oxidative factors in
neural cell differentiation. Finally, theo-
phylline was the only agent that was able to
fully restore the impairment of AC activity
caused by CPF, but it did so only because it
elevated AC by itself, not because it interfered
directly with the effect of CPF. Here again,
although theophylline by itself had adverse
effects on DNA synthesis and indices of cell
number, the possibility remains that analogs
may prove better than the parent compound.
Theophylline is relatively nonspecific as a
phosphodiesterase inhibitor, and we recently
found that CPF targets only a few phospho-
diesterase and AC subtypes (Slotkin and
Seidler 2007). Thus, it may be possible to
ﬁnd an alternative that maintains the protec-
tant effect against CPF while avoiding the
direct adverse effect of theophylline itself.
Although in vitro models are not a substi-
tute for animal studies of protection against
organophosphate-induced developmental
neurotoxicity, our results provide proof that
the proposed divers mechanisms by which
CPF damages developing neurons are indeed
exerted directly by this agent and not indirectly
through complex effects on the maternal–
fetal unit, and further, provide a “proof of
principle” that interventions aimed at these
mechanisms may indeed prove valuable for
amelioration of the adverse effects. However,
the importance of our findings transcends
these issues. Organophosphates represent 50%
of all insecticides used worldwide (Casida and
Quistad 2004), and there is increasing likeli-
hood of human exposures to organophosphate
nerve agents such as those used in the terrorist
incidents in Matsumoto and the Tokyo sub-
way in Japan; therefore, identifying potential
ameliorating therapies is critical. Our ﬁndings
suggest that a cocktail of agents targeting the
various mechanisms for neuronal injury by
organophosphates may prove successful.
Nevertheless, devising an appropriate combina-
tion that avoids harmful effects of the amelio-
rating agents themselves, establishing the
proper doses and pharmacokinetic proﬁles, and
evaluating whether the treatment cocktail
works equally for different organosphosphates
or for the different exposure scenarios in pesti-
cide use versus a terrorist/nerve gas incident
will likely be a daunting task.
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